Fred Fiedorek
Technik-/Wissenschafts-/F&E-Leiter bei VERVE THERAPEUTICS, INC.
Profil
Fred T.
Fiedorek is currently the Chief Medical Officer at Allergan GI Corp.
and Verve Therapeutics, Inc. He previously worked as the SVP, Head-Cardiovascular & Metabolic Development at Bristol Myers Squibb Co., Chief Medical Officer at Rhythm Pharmaceuticals, Inc., Senior Advisor at Foresite Capital Management LLC, and Chief Medical Officer at Intarcia Therapeutics, Inc. He completed his undergraduate degree at Yale University in 1976 and obtained his doctorate from Harvard Medical School in 1981.
Aktive Positionen von Fred Fiedorek
| Unternehmen | Position | Beginn |
|---|---|---|
| VERVE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.09.2023 |
Allergan GI Corp.
 Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Fred Fiedorek
| Unternehmen | Position | Ende |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 15.10.2018 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Foresite Capital Management LLC
 Foresite Capital Management LLC Investment ManagersFinance Foresite Capital Management LLC (Foresite Capital) is a private equity firm founded in 2010 by James Tananbaum. The firm is headquartered in San Francisco. | Berater | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Ausbildung von Fred Fiedorek
| Harvard Medical School | Doctorate Degree |
| Yale University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| VERVE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Allergan GI Corp.
Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Health Technology |
Foresite Capital Management LLC
Foresite Capital Management LLC Investment ManagersFinance Foresite Capital Management LLC (Foresite Capital) is a private equity firm founded in 2010 by James Tananbaum. The firm is headquartered in San Francisco. | Finance |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
